This finding diverges from a preclinical study using tamoxifen-induced adenomyosis in mice, where immunohistochemical analysis revealed high-level COX-2 protein expression in adenomyosis lesions, and pharmacological inhibition by selective COX-2 inhibitor celecoxib markedly reduced adenomyosis severity, including lesion depth, fibrosis, and epithelial–mesenchymal transition (EMT) markers (Jin et al., 2020). The gene discussed is PTGS2; the disease is adenomyosis.